Elon Musk and his Neuralink company's attempt to begin testing brain chips in humans has been rejected by the FDA, according to a report by Reuters.

The request was submitted to the agency last year but according to Reuters, the FDA identified several problematic factors with the technology, including the chip's lithium battery and the potential for small wires to move to other areas of the brain.

"Neuralink doesn't appear to have the mindset and experience that's needed to get this to market anytime soon," Kip Ludwig, former program director for neural engineering at the U.S. National Institute of Health.

There was also a concern of whether or not the chip could be removed without inflicting damage to brain tissue.

What Exactly Is Neuralink?

Musk has claimed the technology could be life-changing for people suffering from paralysis, enabling them to communicate and walk, or it could help repair visual impairment in people.

The chip is supposed to process brain signals that are then transmitted to a device. While human trials for Neuralink have not commenced, there have been versions of the tech that reportedly had some success in animals. However, the company faced pushback and a probe from the U.S. Department of Agriculture after animal cruelty concerns were raised.

Last month Neuralink admitted that at least one monkey was euthanized because of a surgical complication.

Share:
More In Business
October CPI Data Will See Changes in Health Insurance Costs
Ahead of the release of October's consumer inflation data Tuesday, you may notice changes from the Bureau of Labor Statistics. When it comes to how it estimates health insurance costs, the move is expected to give a boost to the U.S. inflation measure which will reverse a trend that has provided some relief.
Some Retailers Reporting Quarterly Results This Week
A handful of retailers will report earnings this week, including Home Depot, Target, Walmart and Macy's, as gas prices peaked in September to the end of this latest quarter while borrowing costs remain at their highest levels in decades.
Load More